share_log

Phio Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Phio Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Phio Pharmaceuticals | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/15 04:51

Moomoo AI 已提取核心訊息

Phio Pharmaceuticals reported Q2 2024 financial results with a net loss of $1.85 million ($3.62 per share), compared to a $2.55 million loss in Q2 2023. Cash and equivalents stood at $4.7 million as of June 30, 2024, down from $8.49 million at year-end 2023. The company completed a $2.6 million financing in July 2024 through warrant exercises.Research and development expenses decreased 37% to $866,000, driven by cost rationalization measures and reduced clinical consulting fees. General and administrative expenses declined 10% to $1.05 million due to lower salary and professional fee expenses. The company terminated its clinical collaboration agreement with AgonOx in May 2024.Phio's lead candidate PH-762 is advancing in a Phase 1b trial for skin cancers, with the first dose cohort completed and dose escalation recommended. The company expects current cash resources to fund operations into Q2 2025 but noted substantial doubt about its ability to continue as a going concern without additional funding.
Phio Pharmaceuticals reported Q2 2024 financial results with a net loss of $1.85 million ($3.62 per share), compared to a $2.55 million loss in Q2 2023. Cash and equivalents stood at $4.7 million as of June 30, 2024, down from $8.49 million at year-end 2023. The company completed a $2.6 million financing in July 2024 through warrant exercises.Research and development expenses decreased 37% to $866,000, driven by cost rationalization measures and reduced clinical consulting fees. General and administrative expenses declined 10% to $1.05 million due to lower salary and professional fee expenses. The company terminated its clinical collaboration agreement with AgonOx in May 2024.Phio's lead candidate PH-762 is advancing in a Phase 1b trial for skin cancers, with the first dose cohort completed and dose escalation recommended. The company expects current cash resources to fund operations into Q2 2025 but noted substantial doubt about its ability to continue as a going concern without additional funding.
Phio Pharmaceuticals公佈2024年第二季度財務結果，淨虧損爲185萬美元（每股3.62美元），相比2023年第二季度的255萬美元虧損有所減少。截至2024年6月30日，公司現金及等價物爲470萬美元，較2023年年末的849萬美元有所下降。公司於2024年7月通過認股權證行使完成了260萬美元的融資。研發費用減少37%，至866,000美元，主要受成本合理化措施和臨牀諮詢費用減少的推動。一般及管理費用下降10%，至105萬美元，原因是薪資和專業費用支出降低。公司於2024年5月終止了與AgonOx的臨牀合作協議。Phio的主導候選藥物PH-762在皮膚癌的10億期試驗中取得進展，首次劑量組已完成，並推薦進行劑量遞增。公司預計當前現金資源將支持運營直到2025年第二季度，但指出在沒有額外融資的情況下繼續作爲持續經營實體的能力存在重大疑慮。
Phio Pharmaceuticals公佈2024年第二季度財務結果，淨虧損爲185萬美元（每股3.62美元），相比2023年第二季度的255萬美元虧損有所減少。截至2024年6月30日，公司現金及等價物爲470萬美元，較2023年年末的849萬美元有所下降。公司於2024年7月通過認股權證行使完成了260萬美元的融資。研發費用減少37%，至866,000美元，主要受成本合理化措施和臨牀諮詢費用減少的推動。一般及管理費用下降10%，至105萬美元，原因是薪資和專業費用支出降低。公司於2024年5月終止了與AgonOx的臨牀合作協議。Phio的主導候選藥物PH-762在皮膚癌的10億期試驗中取得進展，首次劑量組已完成，並推薦進行劑量遞增。公司預計當前現金資源將支持運營直到2025年第二季度，但指出在沒有額外融資的情況下繼續作爲持續經營實體的能力存在重大疑慮。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間